Warfarinbehandling ved atrieflimmer i allmennpraksis - undervurderes blødningsrisikoen?

Tidsskrift for den Norske Laegeforening

Volumn 134, Issue 2, 2014, Pages 175-179

  Bratland, Bjørn ^a   Hornnes, Magn Bjørn ^a  

^a Legegruppen Grandgarden   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; FEMALE; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; METHODOLOGY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; GENERAL PRACTICE; HEMORRHAGE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; WARFARIN;

EID: 84893590411     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.13.0626     Document Type: Article

References (21)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
2. Risøe C, Gjesdal K. Antikoagulasjonsbehandling ved forbigående atrieflimmer. Tidsskr Nor Lægeforen 2004; 124: 950-2.
3. Camm AJ, Lip GY, Caterina R et al. 2012 focused update of the ESC Guidelines for the mangagement of atrial fibrillation. Eur Heart J 2012; 33: 2719-47.
4. Aamodt AH, Sandset PM, Atar D et al. Atrieflimmer og hjerneslag. Tidsskr Nor Legeforen 2013; 133: 1453-7.
5. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.
6. Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fribrillation: nationwide cohort study. BMJ 2011; 342: 1-9.
7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
8. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
9. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
10. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
11. Wieloch M, Själander A, Frykman V et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thromboembolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32: 2282-9.
12. Bratland B. Warfarinbehandling i allmennpraksis. Tidsskr Nor Lægeforen 2006; 126: 162-5.
13. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
14. Lip GY, Frison L, Halperin JL et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-80.
15. Reikvam Å, Sandset PM, red. Warfarinbehandling i praksis-tryggere antikoagulasjon. 2. utg. Skriftserie for leger: Utdanning og kvalitetsutvikling. Oslo: Den norske legeforening, 2010. http://legeforeningen.no/PageFiles/25973/Warfarinbehandling%20i%20praksis.pdf (6.12.2013).
16. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-34.
17. Ingen bedring i slagforebygging. Pressemelding fra ESC 2013. Dagens Medisin 4.9.2013.
18. Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
19. Nasjonal rådgivende spesialistgruppe innen antikoagulasjon. Informasjon om de nye perorale antikoagulasjonsmidlene dabigatran, rivaroksaban og apiksaban. Oslo: Helsedirektoratet, Statens legemiddelverk, 2013.
20. Ghanima W, Atar D, Sandset PM. Nye perorale antikoagulasjonsmidler-en oversikt. Tidsskr Nor Legeforen 2013; 133: 1940-5.
21. Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation. Oslo: Nasjonalt kunnskapssenter for helsetjenesten, 2013. www.kunnskapssenteret.no/publikasjoner/efficacy-and-cost-effectiveness-ofnew-oral-anticoagulants-compared-to-warfarinfor-the-prevention-of-stroke-in-patients-withatrial-fibrillation?language=english (6.12.2013).